Research programme: meprin protease inhibitors - Vivoryon Therapeutics
Latest Information Update: 30 Jun 2023
Price :
$50 *
At a glance
- Originator Vivoryon Therapeutics
- Class Antifibrotics; Antiulcers; Hydroxamic acids; Hydroxylamines; Small molecules
- Mechanism of Action Tiopronin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Acute kidney injury; Fibrosis
Most Recent Events
- 27 Apr 2023 Research programme: meprin protease inhibitors - Vivoryon Therapeutics is available for licensing as of 27 Apr 2023. https://www.vivoryon.com/about-us/partnering/
- 27 Apr 2023 Vivoryon Therapeutics has patent pending for "Novel inhibitors of meprin alpha and beta" in multiple countries worldwide
- 27 Apr 2023 Vivoryon Therapeutics has patent protection for "Novel inhibitors of meprin alpha and beta" in US, Australia, China, Spain, Europian Union, and Japan